Rankings
▼
Calendar
PCRX (Pacira BioSciences, Inc.) Stock Financials & Earnings | Market Cap Arena
PCRX
Pacira BioSciences, Inc.
Mkt Cap
$971M
Healthcare
·
Drug Manufacturers - Specialty & Generic
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$726M
Net Income (TTM)
$7M
EPS (TTM)
$0.15
Free Cash Flow (TTM)
$137M
Gross Margin
71.5%
Op. Margin
3.9%
Net Margin
1.0%
FCF Margin
18.8%
P/S Ratio (TTM)
1.3x
P/E Ratio (TTM)
138.1x
YoY Rev Growth
+3.6%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$160M
$111M
-$3M
Q2 23
$169M
$121M
$40M
Q3 23
$164M
$124M
$18M
Q4 23
$181M
$134M
$33M
Q1 24
$167M
$120M
$13M
Q2 24
$178M
$134M
$28M
Q3 24
$169M
$130M
-$140M
Q4 24
$187M
$147M
$25M
Q1 25
$169M
$135M
$2M
Q2 25
$181M
$140M
$8M
Q3 25
$180M
$145M
$6M
Q4 25
$197M
$99M
$11M
marketcaparena.com
Revenue Breakdown
PCRX
Pacira BioSciences, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
1.5x
—
Q2 23
1.5x
—
Q3 23
1.5x
139.1x
Q4 23
1.4x
23.2x
Q1 24
1.4x
13.8x
Q2 24
1.4x
15.3x
Q3 24
1.4x
—
Q4 24
1.4x
—
Q1 25
1.4x
—
Q2 25
1.4x
—
Q3 25
1.4x
45.3x
Q4 25
1.3x
138.1x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
$19M
$13M
Q2 23
$43M
$40M
Q3 23
$44M
$41M
Q4 23
$48M
$46M
Q1 24
$49M
$46M
Q2 24
$53M
$52M
Q3 24
$54M
$50M
Q4 24
$33M
$31M
Q1 25
$35M
$27M
Q2 25
$12M
$9M
Q3 25
$61M
$57M
Q4 25
$44M
$43M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$7M
Q2 23
$3M
Q3 23
$3M
Q4 23
$2M
Q1 24
$3M
Q2 24
$2M
Q3 24
$4M
Q4 24
$2M
Q1 25
$9M
Q2 25
$3M
Q3 25
$4M
Q4 25
$218K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+1.5%
+16.2%
Q2 23
+0.0%
-6.2%
Q3 23
-2.1%
+0.0%
Q4 23
+5.4%
-18.6%
Q1 24
+4.2%
-5.8%
Q2 24
+5.0%
+15.6%
Q3 24
+2.8%
+110.7%
Q4 24
+3.3%
+9.8%
Q1 25
+1.1%
+8.5%
Q2 25
+1.7%
+15.2%
Q3 25
+6.5%
-43.8%
Q4 25
+5.1%
+14.2%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$12M
7.5%
Q2 23
$11M
6.5%
Q3 23
$13M
7.6%
Q4 23
$12M
6.9%
Q1 24
$13M
7.9%
Q2 24
$13M
7.0%
Q3 24
$13M
7.8%
Q4 24
$12M
6.6%
Q1 25
$15M
8.6%
Q2 25
$15M
8.5%
Q3 25
$14M
7.8%
Q4 25
$13M
6.9%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$17M
$29M
$42M
—
Q2 23
$19M
$27M
$37M
—
Q3 23
$21M
$30M
$38M
—
Q4 23
$19M
$30M
$36M
—
Q1 24
$18M
$33M
$39M
—
Q2 24
$20M
$29M
$39M
—
Q3 24
$19M
$31M
$43M
—
Q4 24
$24M
$29M
$50M
—
Q1 25
$25M
$31M
$56M
—
Q2 25
$28M
$38M
$51M
—
Q3 25
$26M
$33M
$58M
—
Q4 25
$37M
—
—
$102M
marketcaparena.com
Revenue Segments
Quarter
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$36M
$138M
$174M
Q2 23
$87M
$134M
$221M
Q3 23
$99M
$136M
$235M
Q4 23
$153M
$125M
$279M
Q1 24
$184M
$142M
$326M
Q2 24
$247M
$157M
$404M
Q3 24
$246M
$208M
$454M
Q4 24
$277M
$208M
$485M
Q1 25
$284M
$210M
$494M
Q2 25
$300M
$145M
$446M
Q3 25
$148M
$99M
$246M
Q4 25
$159M
$80M
$238M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
46M
+0.1%
Q2 23
52M
+13.3%
Q3 23
52M
+0.0%
Q4 23
52M
-0.0%
Q1 24
52M
+0.2%
Q2 24
51M
-3.2%
Q3 24
46M
-8.7%
Q4 24
49M
+6.3%
Q1 25
47M
-5.1%
Q2 25
45M
-2.3%
Q3 25
44M
-2.2%
Q4 25
43M
-3.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$442K
447
FY 15
$511K
487
FY 16
$549K
503
FY 17
$586K
489
FY 18
$651K
518
FY 19
$695K
606
FY 20
$689K
624
FY 21
$777K
697
FY 22
$933K
715
FY 23
$948K
712
FY 24
$887K
790
FY 25
$876K
829
marketcaparena.com